Biosimilars 20/20 Conference Scheduled for June

The Biosimilars 20/20 Conference, a two-day event that will provide an indepth look into the future of the biosimilars market and address challenges of implementation, is scheduled for June 3 and 4 at The Hub in Philadelphia, Pa. The conference will open with a session featuring an examination and five-year projections of the expected sequence of biosimilar approval for parent drugs. It will also outline key opportunities expected to emerge during biosimilars’ first five years of market entry in the U.S., as well as analyze trends in Europe. Additional sessions will address perspectives from physicians and payers, the value and means of patient education, interchangeability, legal/regulatory aspects, biosimilars in the market, research and development, health information technology and its impact on biosimilars, and more. More information about the conference can be found at biosimilars.specialtycme.org.